Sars-Cov Infection

A first-in-human trial of a nasal COVID-19 vaccine candidate began enrolling adults aged 18 to 64 years who have received at least three prior doses of a COVID-19 messenger RNA vaccine, according to the NIH.

Approximately one-quarter of adults who lost taste or smell following SARS-CoV-2 infection reported partial or no recovery of their senses, a study published in The Laryngoscope found.

Upamostat reduced hospitalizations for COVID-19 by 100% and significantly reduced the development of new, severe symptoms when administered early to symptomatic patients, according to a press release from the manufacturer.

Initial findings indicate that a passive air sampler clip can detect airborne SARS-CoV-2 indoors and may provide a way for individuals in high-risk settings to assess their personal exposure to the virus.

A novel breathalyzer detected SARS-CoV-2 in critically ill patients with 88% accuracy, according to findings published in PLOS ONE.

Researchers in the United Kingdom reported “reassuring” data on the 1-year outcomes of dozens of children who had a serious inflammatory syndrome triggered by SARS-CoV-2 infection.

A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.

A 43-year-old man in the United States tested positive for SARS-CoV-2 twice within 4 months, according to a paper in BMJ Case Reports.

SARS-CoV-2 infectiousness appears to peak in the upper respiratory tract in the first week of illness — earlier than other coronaviruses, which may explain the rapid spread of COVID-19, according to researchers.

Risk for infection with SARS-CoV-2 — the novel coronavirus that causes COVID-19 — appeared more than twice as high among individuals with cancer than the general population, according to an analysis of data from a tertiary care hospital in Wuhan, China.